VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ASND
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ASNDAscendis Pharma A/S
$271.19$16.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ASND logo

Ascendis Pharma A/S

ASND
NASDAQ · Rare Disease Biotech
$271.19
At close - Nov 17, 4:00 PM EST - USD
Market Cap$16.84B
P/E19.0x
52W High$282.15
Volume585.24K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Commercial Ramp Lifts Ascendis Toward Sustained Profitability

Ascendis Pharma's revenue scaled from $36.0M in 2024Q2 to $367.5M in 2026Q3, with trailing growth near 90% suggesting its launched therapies are gaining commercial traction.

GrowthExpanding
ProfitabilityWeak
ValuationAttractive
TechnicalsStrong
Explore valuation models
MARKET ACTION

ASND price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-53% Peers

P/E is 53% below peer median

03

Market leadership

RS 80 · Leader

High momentum (Outperforming 80% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 12
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue expanded to $367.5M in 2026Q3 with a 91.2% gross margin, though a 33.7% operating margin and 20.0% net margin indicate that operating costs still absorb much of the gross profit.

Analyst Consensus+13.5% target
Buy(26 analysts)
24 Buy2 Hold0 Sell

The Bull Case

Upside Catalysts

Transcon platform potential

Ascendis Pharma's Transcon platform is highlighted as a key driver, offering innovative solutions in drug delivery and development.

Rare disease pipeline

The company's focus on rare diseases presents significant growth opportunities due to high unmet medical needs and favorable pricing.

Recent trial successes

Positive results from recent clinical trials bolster confidence in the company's ability to bring new therapies to market.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ASND+27.15%
S&P 500 (^GSPC)+7.21%
1-Year Return
ASND+25.23%
S&P 500 (^GSPC)+10.03%
3-Year Return
ASND+185.49%
S&P 500 (^GSPC)+59.00%
5-Year Return
ASND+75.01%
S&P 500 (^GSPC)+58.24%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
19.0x
Forward P/EExpansion
18.7x
EV/EBITDA
64.7x
FCF YieldCash Flow
3.4%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
19.0x
N/A
N/A
EV/EBITDA
64.7x
N/A
N/A
Price/FCF
29.6x
296.3x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$16.49-93.9%
Base (Fair)$231.88-15.8%
Bull$40.56-85.0%
$16.49 Bear$231.88 Base$40.56 Bull
Current Market Price: $271.19
Trades at a 17.0% premium to Base DCF ($231.88)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$692M+90.2% YoY
Net income FY25
-$219M+42.1% YoY
Free cash flow FY25
$44M+114.2% YoY
Operating margin FY25
-18.9%+57.7 pts YoY
ROIC (FY25)-69.1%
Avg ROIC 5Y-85.4%
ROE (TTM)108.3%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
$1.24+38.7%
vs $0.89
$419M+2.3%
vs $409M
Q3 2026
Aug 13, 2026
$3.29+92.4%
vs $1.71
$387M+2.8%
vs $377M
Q2 2026
May 7, 2026
$0.32+70.6%
vs $0.19
$285M-7.8%
vs $309M
Q1 2026
Feb 11, 2026
-$0.64-966.7%
vs -$0.06
$345M+18.0%
vs $292M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·1d ago
Ascendis Pharma A/S (ASND) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Ascendis Pharma A/S (ASND) Jefferies Global Healthcare Conference 2026 November 17, 2026 6:30 AM EST Company Participants Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP & Member of Executive Board Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Presentation Faisal Khurshid Jefferies LLC, Research Division All right. Good morning, everyone.

MarketBeat·6d ago
Ascendis Pharma A/S Q3 Earnings Call Highlights

Ascendis Pharma A/S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched achondroplasia drug YUVIWEL grew.

Seeking Alpha·6d ago
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript

GlobeNewsWire·6d ago
Ascendis Pharma Reports Third Quarter 2026 Financial Results

Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation for TransCon ® CNP Final EC decision for TransCon CNP expected in Q4 2026; first EU launch planned in Germany in Q1 2027 Presented Week 52 sentinel cohort data in infants with achondroplasia aged 0 to

Filtered for Ascendis Pharma A/SMore Headlines
04

Compare before deciding

Benchmark ASND against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Ascendis Pharma A/S (ASND)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ASND logoASNDAscendis Pharma A/SCurrent
$271.19$16.84B19.0390.22%73.69%108.33%—
IONS logoIONSIonis Pharmaceuticals, Inc.
$26.96$4.48B-8.2033.87%-56.9%-120.44%—
INCY logoINCYIncyte Corporation
$119.09$24.14B60.0021.22%6.71%7.11%—
ALKS logoALKSAlkermes plc
$45.45$7.62B-9999.00-5.25%-0.02%-0.02%—
JAZZ logoJAZZJazz Pharmaceuticals plc
$240.71$15.12B75.624.88%4.37%4.62%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.32$3.14B8.8711.87%30.13%28.03%—

Compare ASND vs Peers

Ascendis Pharma A/S (ASND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IONS

Most directly comparable listed peer for ASND.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ASND against a more recognizable public peer.

Peer Set

Compare Top 5

vs IONS, INCY, ALKS, JAZZ

Get notified when ASND posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ASND Frequently Asked Questions

Ascendis Pharma A/S (ASND) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Ascendis Pharma A/S's revenue?

Ascendis Pharma A/S (ASND) reported $1.21B in revenue over the trailing twelve months. Revenue was $691.7M in fiscal year 2025. That is 4339% more than the $15.6M of fiscal year 2012.

How fast is Ascendis Pharma A/S growing?

Ascendis Pharma A/S (ASND) grew revenue by 86.9% over the trailing twelve months, compared with the twelve months before.

Is ASND profitable?

Yes. Ascendis Pharma A/S (ASND) earned $890.4M in net income over the trailing twelve months (a 73.7% net margin).

Dividend & Returns
What is ASND's return on equity?

Ascendis Pharma A/S (ASND) had a return on equity (ROE) of 108.3% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Ascendis Pharma A/S's free cash flow?

Ascendis Pharma A/S (ASND) generated $516.9M in free cash flow over the trailing twelve months.

What if you invested $1,000 in ASND back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →